Cargando…

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19

Background: This study aims to evaluate the real-world effectiveness of regdanvimab on clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19). Methods: This retrospective observational study included 152 patients (89 received regdanvimab and 63 did not) diagnosed wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Taeyun, Joo, Dong-Hyun, Lee, Seung Woo, Lee, Jaejun, Lee, Sang Jin, Kang, Jihun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911404/ https://www.ncbi.nlm.nih.gov/pubmed/35268503 http://dx.doi.org/10.3390/jcm11051412

Ejemplares similares

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
por: Hong, Sun In, et al.
Publicado: (2022)

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
por: Lee, Shinwon, et al.
Publicado: (2022)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Publicado: (2023)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
por: Ison, Michael G, et al.
Publicado: (2021)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
por: Kim, Haein, et al.
Publicado: (2023)

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
por: Lee, Jaejun, et al.
Publicado: (2022)

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data
por: Kang, Minjae, et al.
Publicado: (2022)

Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data
por: Kim, Taeyun, et al.
Publicado: (2022)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

Muscle Mass Adjusted for Body Weight Is Associated with Significant Liver Fibrosis in Young Adults with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Korean Military Hospital
por: Lee, Jaejun, et al.
Publicado: (2023)

Association Between Serum Retinol and α-Tocopherol Levels and Metabolic Syndrome in Korean General Population: Analysis of Population-Based Nationally Representative Data
por: Kim, Taeyun, et al.
Publicado: (2020)

Association between dual use of e-cigarette and cigarette and chronic obstructive pulmonary disease: an analysis of a nationwide representative sample from 2013 to 2018
por: Kim, Taeyun, et al.
Publicado: (2021)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
por: Lee, Ji Yeon, et al.
Publicado: (2023)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer’s Disease Dementia
por: Hsieh, Sun-Wung, et al.
Publicado: (2021)

Comparative efficacy of inhalers in mild-to-moderate asthma: systematic review and network meta-analysis
por: Park, Hyung Jun, et al.
Publicado: (2022)

Association of electronic cigarette exposure with serum uric acid level and hyperuricemia: 2016-2017 Korea National Health and Nutritional Examination Survey
por: Kim, Taeyun, et al.
Publicado: (2021)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
por: Chae, Ganghee, et al.
Publicado: (2022)

Sirolimus Conversion Efficacy for Graft Function Improvement and Histopathology in Renal Recipients with Mild to Moderate Renal Insufficiency
por: Joo, Dong Jin, et al.
Publicado: (2014)

Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience
por: Min, Gi-June, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gp5ft5iasffgn101h8a5o7nc7s